Morgan Stanley
IMNM icon

Morgan Stanley’s Immunome IMNM Stock Holding History

Morgan Stanley’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51M Sell
2,407,942
-433,647
-15% -$9.28M ﹤0.01% 2194
2026
Q1 		$62.1M Buy
2,841,589
+1,132,500
+66% +$25.2M ﹤0.01% 1874
2025
Q4 		$36.7M Sell
1,709,089
-124,729
-7% -$2.19M ﹤0.01% 2381
2025
Q3 		$21.5M Buy
1,833,818
+1,429,461
+354% +$14.2M ﹤0.01% 2819
2025
Q2 		$3.76M Sell
404,357
-459,866
-53% -$3.77M ﹤0.01% 4289
2025
Q1 		$5.82M Buy
864,223
+465,356
+117% +$4.46M ﹤0.01% 3795
2024
Q4 		$4.24M Buy
398,867
+109,789
+38% +$1.33M ﹤0.01% 4137
2024
Q3 		$4.23M Sell
289,078
-82,880
-22% -$1.18M ﹤0.01% 4086
2024
Q2 		$4.5M Buy
371,958
+222,561
+149% +$3.48M ﹤0.01% 3978
2024
Q1 		$3.69M Buy
149,397
+137,242
+1,129% +$2.79M ﹤0.01% 4162
2023
Q4 		$130K Hold
12,155
– – ﹤0.01% 5847
2023
Q3 		$101K Sell
12,155
-1,311
-10% -$9.63K ﹤0.01% 5889
2023
Q2 		$107K Buy
13,466
+1,336
+11% +$7.31K ﹤0.01% 5926
2023
Q1 		$60.5K Hold
12,130
– – ﹤0.01% 6212
2022
Q4 		$26.8K Sell
12,130
-4
-0% -$16 ﹤0.01% 6552
2022
Q3 		$53K Sell
12,134
-796
-6% -$3.73K ﹤0.01% 6379
2022
Q2 		$41K Sell
12,930
-802
-6% -$2.92K ﹤0.01% 6692
2022
Q1 		$78K Sell
13,732
-64,983
-83% -$486K ﹤0.01% 6468
2021
Q4 		$1.02M Buy
78,715
+64,629
+459% +$1.15M ﹤0.01% 5055
2021
Q3 		$343K Buy
14,086
+2,715
+24% +$47.4K ﹤0.01% 5709
2021
Q2 		$196K Buy
11,371
+11,251
+9,376% +$249K ﹤0.01% 6026
2021
Q1 		$4K Sell
120
-2,128
-95% -$52.9K ﹤0.01% 7151
2020
Q4 		$22K Buy
+2,248
New +$26.2K ﹤0.01% 6404

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Morgan Stanley's IMNM Position: Q2 2026 in Review

Morgan Stanley reduced its Immunome (IMNM) stake by 15% in Q2 2026, selling an estimated $9.28M and leaving 2,407,942 shares worth $51M. The position accounts for ﹤0.01% of the portfolio, ranked #2194.

Morgan Stanley first reported a position in IMNM in Q4 2020 and has held it in 23 quarters since. The position peaked at $62.1M in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Morgan Stanley held 2,407,942 shares of Immunome worth $51M as of Q2 2026.
  • Morgan Stanley sold 433,647 Immunome shares in Q2 2026, an estimated $9.28M.
  • Immunome made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2194 holding.
  • Morgan Stanley first reported a position in Immunome in Q4 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Immunome position peaked at $62.1M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.